CCP
TEVA icon

Corient Capital Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Corient Capital Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12,242
Closed -$98K – 768
2021
Q4 		$98K Sell
12,242
-1,512
-11% -$13.6K 0.01% 696
2021
Q3 		$134K Buy
+13,754
New +$129K 0.01% 669

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Corient Capital Partners's TEVA Position: Q1 2022 in Review

Corient Capital Partners sold out of Teva Pharmaceuticals (TEVA) in Q1 2022, closing a stake of 12,242 shares — an estimated $98K sold.

Corient Capital Partners first reported a position in TEVA in Q3 2021 and held it in 2 quarters. The position peaked at $134K in Q3 2021. 438 funds tracked by Wall St. Rank hold TEVA as of Q1 2022.

  • Corient Capital Partners reported no remaining Teva Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Corient Capital Partners sold 12,242 Teva Pharmaceuticals shares in Q1 2022, an estimated $98K.
  • Corient Capital Partners first reported a position in Teva Pharmaceuticals in Q3 2021 and held it in 2 quarters.
  • Corient Capital Partners's Teva Pharmaceuticals position peaked at $134K in Q3 2021.
  • 438 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2022.

Based on Corient Capital Partners's 13F filing for Q1 2022, filed 16 May 2022.